GlassScriptPhysician profile
Kyle J Linsey
NPI 1194164517
$3,880.29
in general payments reported to CMS, 2019-2025
24 companies · $1,249 in 2025
The $1,249 reported for 2025 was more than what 82% of Ophthalmology providers received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $116 · 2020: $113 · 2021: $707 · 2022: $722 · 2023: $310 · 2024: $664 · 2025: $1,249.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,205 · Education: $17.84.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,204.83 |
| Education | $17.84 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sun Pharmaceutical Industries INC. | $525.07 | 2019-2025 | Cequa |
| Abbvie INC. | $518.94 | 2022-2025 | |
| Bausch & Lomb Americas INC. | $447.26 | 2022-2025 | Miebo, Vyzulta, Xiidra |
| Harrow Eye, LLC | $446.87 | 2024-2025 | Triesence, Iheezo, Vevye |
| Allergan, INC. | $350.33 | 2020-2022 | |
| Notal Vision, INC. | $256.18 | 2022 | |
| Johnson & Johnson Surgical Vision, INC. | $181.35 | 2021-2025 | Tecnis Iol |
| Kala Pharmaceuticals, INC. | $177.00 | 2019-2022 | |
| Alcon Vision LLC | $176.44 | 2021-2025 | Clareon, Eysuvis, Tryptyr |
| Tarsus Pharmaceuticals, INC. | $132.13 | 2024-2025 | Xdemvy |
| Astellas Pharma US INC | $117.85 | 2024-2025 | Izervay |
| Genentech USA, INC. | $97.71 | 2022-2024 | Vabysmo |
| Novartis Pharmaceuticals Corporation | $95.74 | 2021-2023 | |
| Eyevance Pharmaceuticals LLC | $82.79 | 2020-2022 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $66.27 | 2019-2021 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Horizon Therapeutics Plc | $63.46 | 2021-2022 | |
| Sight Sciences, INC. | $27.16 | 2021 | |
| Apellis Pharmaceuticals, INC. | $25.30 | 2023 | Syfovre |
| Akorn Operating Company LLC | $23.78 | 2021 | |
| Carl Zeiss Meditec Cataract Technology INC. | $15.74 | 2021 | |
| Optos, INC. | $14.88 | 2021 | |
| Dompe US, INC. | $13.26 | 2019 | |
| Shire North American Group INC | $12.90 | 2019 | |
| Aerie Pharmaceuticals, INC. | $11.88 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kyle Linsey listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.